Indenza 40mg Capsule is an anti-cancer medication that contains Enzalutamide, used primarily in the treatment of prostate cancer.
| Composition | Enzalutamide 40mg |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Obnyx 40mg contains Enzalutamide, an oral anti-cancer medication used to treat metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men.
| Composition | Enzalutamide |
| Manufacturer | Zydus Cadila |
| Packing | 28 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Xylutide 40mg Capsule contains Enzalutamide, a medication used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer.
| Composition | Enzalutamide |
| Manufacturer | Cipla Ltd |
| Packing | 28 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Glenza 40 mg capsule has enzalutamide in it and is used to treat advanced prostate cancer, particularly in men whose cancer does not respond to hormone therapy, regardless of whether it has spread to other parts of the body.
| Composition | Enzalutamide |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Packing | 28 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Enzyl 40mg capsule is an oral anti-cancer medication containing Enzalutamide, primarily used to treat advanced prostate cancer, especially castration-resistant prostate cancer (CRPC).
| Composition | Enzalutamide |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Enzana 40mg Capsule contains Enzalutamide, a medication used to treat prostate cancer that has spread or is resistant to standard hormone therapy.
| Composition | Enzalutamide |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 56 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Enzamide 40 mg contains enzalutamide, a nonsteroidal androgen receptor inhibitor prescribed primarily for castration-resistant prostate cancer (CRPC)—both metastatic (spread beyond the prostate) and non-metastatic forms.
| Composition | Enzalutamide |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packing | 56 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Bdenza 40mg Capsule contains Enzalutamide, a potent anti-androgen medication used in the treatment of advanced prostate cancer
| Composition | Enzalutamide |
| Manufacturer | Prakash Biopharma |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Azel 40mg Capsule is a prescription medicine that contains enzalutamide, a powerful androgen receptor inhibitor, and it is mainly prescribed for the treatment of advanced prostate cancer.
| Composition | Enzalutamide |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
